China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the “Group”) is a well-established, innovation-driven specialty pharma with a focus on sales & marketing in China. The Group was established in 1995, and was listed on the Main Board Market of the Stock Exchange of Hong Kong Limited (stock code: 867) on 28 September 2010. CMS has been included in the Morgan Stanley Capital International (MSCI) China Index as well as the Hang Seng Stock Connect Biotech 50 Index (HSSCB50), and is the object of transaction in both Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. The Group is also the largest shareholder of Tibet Rhodiola Pharmaceutical Holding Co. (stock code: 600211), a listed company of Shanghai Stock Exchange (A-share).

By capitalizing on its resources of global product development for more than two decades, as well as its market reputation, CMS has established the strategic cooperation with a number of leading pharmaceutical companies around the world and made equity investments in R&D companies from the UK, France, the US and Switzerland. The Group’s innovative pipeline includes the products with great market potential and competitive differentiation advantages at relatively high innovation level and with a wide range of therapeutic areas. CMS has become a trustworthy and highly recognized cooperation partner for world’s leading pharmaceutical and innovative R&D companies who are willing to enter China market.

With the benefits of its proven and successful experiences in drug commercialization for over two decades, the Group has created good sales records for a number of quality branded drugs and received the high recognition from dozens of world’s leading pharmaceutical companies. The Group concentrates on exploring the evidence-based medical evidence and differentiation competitive advantages of the drugs, and has established a professional, compliant and efficient academic promotion system. Combined with its timely, refined, transparent and efficient internal management system, the Group has become one of the most efficient pharmaceutical companies in the field of marketing and promotion of prescription drugs.

Along with the value chain of pharmaceutical industry, CMS has paid special attention to two core elements, product competence and promotion capability. Over the past decade (from 2010 to 2019), the Group has achieved the rapid growth with a turnover compound annual growth rate (“CAGR”) of 25.6%, and a net profit CAGR of 28.4%. The Group’s return on equity has maintained over 20% for more than a decade. By converging the R&D forces and innovative resources around the world, CMS will work diligently to fulfill its mission to continually introduce more affordable innovative products with differentiation competitive advantages to benefit more Chinese patients and their families.

中国医疗系统控股有限公司（以下简称“ CMS”）及其子公司（“集团”）是一家以创新为导向的成熟专业药房，专注于在中国的销售和营销。该集团成立于1995年，并于2010年9月28日在香港联合交易所有限公司的主板市场（股票代码：867）上市。CMS被纳入摩根士丹利资本国际（MSCI）中国指数，包括：以及恒生沪深港通生物技术50指数（HSSCB50），是沪港通和深港通的交易对象。集团还是上海证券交易所（A股）上市公司西藏红景天医药控股有限公司（股票代码：600211）的最大股东。

凭借超过二十年的全球产品开发资源以及其市场声誉，CMS已与全球多家领先的制药公司建立了战略合作关系，并对英国，法国的研发公司进行了股权投资。 ，美国和瑞士。本集团的创新渠道包括具有较高市场潜力和竞争优势的产品，具有相对较高的创新水平和广泛的治疗领域。CMS已成为愿意进入中国市场的全球领先制药和创新研发公司的值得信赖和高度认可的合作伙伴。

凭借二十多年在药品商业化方面久经考验和成功的经验，该集团为许多优质品牌药品创造了良好的销售记录，并赢得了数十家世界领先制药公司的高度认可。集团专注于探索循证医学证据和差异化竞争优势，并建立了专业，合规和高效的学术促进体系。结合其及时，完善，透明和高效的内部管理体系，本集团已成为处方药营销和推广领域中最高效的制药公司之一。

伴随着制药行业的价值链，CMS特别关注两个核心要素，即产品能力和促销能力。在过去十年（2010年至2019年）中，本集团实现了快速增长，营业额复合年增长率（“ CAGR”）为25.6％，净利润复合增长率为28.4％。十多年来，集团的股本回报率一直保持20％以上。通过融合全球研发力量和创新资源，CMS将不懈努力，以实现其使命，不断推出具有差异化竞争优势的价格更可承受的创新产品，以使更多的中国患者及其家人受益。